- Home
- INMB vs ASRT Comparison
INMB vs ASRT Comparison
Compare INMB & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ASRT
- Stock Information
- Founded
- INMB 2015
- ASRT 1995
- Country
- INMB United States
- ASRT United States
- Employees
- INMB N/A
- ASRT N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ASRT Health Care
- Exchange
- INMB Nasdaq
- ASRT Nasdaq
- Market Cap
- INMB 68.9M
- ASRT 79.1M
- IPO Year
- INMB 2019
- ASRT 1997
- Fundamental
- Price
- INMB $2.53
- ASRT $0.81
- Analyst Decision
- INMB Buy
- ASRT Strong Buy
- Analyst Count
- INMB 4
- ASRT 1
- Target Price
- INMB $9.53
- ASRT $3.00
- AVG Volume (30 Days)
- INMB 2.9M
- ASRT 289.6K
- Earning Date
- INMB 08-07-2025
- ASRT 08-11-2025
- Dividend Yield
- INMB N/A
- ASRT N/A
- EPS Growth
- INMB N/A
- ASRT N/A
- EPS
- INMB N/A
- ASRT N/A
- Revenue
- INMB $50,000.00
- ASRT $117,099,000.00
- Revenue This Year
- INMB $212.27
- ASRT N/A
- Revenue Next Year
- INMB $10,184.28
- ASRT $11.91
- P/E Ratio
- INMB N/A
- ASRT N/A
- Revenue Growth
- INMB N/A
- ASRT N/A
- 52 Week Low
- INMB $1.89
- ASRT $0.51
- 52 Week High
- INMB $11.64
- ASRT $1.38
- Technical
- Relative Strength Index (RSI)
- INMB 41.61
- ASRT 66.13
- Support Level
- INMB $2.42
- ASRT $0.71
- Resistance Level
- INMB $2.61
- ASRT $0.86
- Average True Range (ATR)
- INMB 0.22
- ASRT 0.03
- MACD
- INMB 0.09
- ASRT 0.01
- Stochastic Oscillator
- INMB 26.67
- ASRT 70.69
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.